Pirenzepine in the Treatment of Reflux Oesophagitis: A Placebo-Controlled, Double-Blind Study

S. Niemelä Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

T. Jääskeläinen Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

J. Lehtola Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

J. Martikainen Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

I. Krekelä Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

S. Sarna Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

H. Sarelin Gastroenterological Unit, Dept. of Internal Medicine, Oulu University Central Hospital, Oulu, Finland; Dept. of Internal Medicine, Lansi-Pohja Central Hospital, Dept. of Pathology, Kainuu Central Hospital, Helsinki, Finland; Dept. of Public Health, University of Helsinki, Helsinki, Finland; Medical Research Dept., Panfarma Oy/Boehringer Ingelheim, Helsinki, Finland

show all

Abstract

The efficacy of 50 mg pirenzepine twice daily in the treatment of reflux oesophagitis was compared with that of placebo in 47 patients over a period of 12 weeks. The 23 patients receiving pirenzepine experienced decreases in symptoms after 4 weeks (p < 0.001) and 12 weeks (p < 0.02) of treatment significantly greater than those in the 24 patients receiving placebo. The decreases in symptoms were associated with significantly less use of antacids by the pirenzepine group (p < 0.01) during the first 4 weeks. Endoscopically, oesophagitis was healed or improved in 54.5% of patients receiving pirenzepine and in 18.2% of patients receiving placebo (p < 0.05) after 4 weeks of treatment. After 12 weeks of treatment healing or improvement was seen in 55.0% and 35.0% of patients, respectively (difference not significant). Histologic improvement did not differ significantly between the groups. Our results suggest that pirenzepine is useful in the management of reflux oesophagitis.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Pirenzepine in the Treatment of Reflux Oesophagitis: A Placebo-Controlled, Double-Blind Study

Information for

Open access

Opportunities

Help and information

Pirenzepine in the Treatment of Reflux Oesophagitis: A Placebo-Controlled, Double-Blind Study

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature